BioNTech Announces New ADS Repurchase Program
28 Março 2023 - 7:45AM
BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today
announced that it has entered into a new share repurchase program
(the “Program”), pursuant to which the Company may purchase
American Depositary Shares, each representing one ordinary share
(“ADS”), of the Company in the amount of up to $0.5 billion during
the remainder of 2023. BioNTech expects to use all or a portion of
the repurchased ADSs and the ADSs held in treasury to satisfy
upcoming settlement obligations under the Company’s share-based
payment arrangements.
The timing and total amount of ADS repurchases
will depend upon market conditions and may be made in open market
purchases from time to time. The share repurchase program announced
on March 31, 2022 of up to $1.5bn concluded on March 17, 2023 with
a total repurchase amount of $1.3bn.
The Program has been designed to operate within
the safe harbor provided by Rule 10b-18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), and the affirmative
defense provided by Rule 10b5-1 of the Exchange Act.
About BioNTechBiopharmaceutical New
Technologies is a next generation immunotherapy company pioneering
novel therapies for cancer and other serious diseases. The Company
exploits a wide array of computational discovery and therapeutic
drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor T cells,
bi-specific checkpoint immuno-modulators, targeted cancer
antibodies and small molecules. Based on its deep expertise in mRNA
vaccine development and in-house manufacturing capabilities,
BioNTech and its collaborators are developing multiple mRNA vaccine
candidates for a range of infectious diseases alongside its diverse
oncology pipeline. BioNTech has established a broad set of
relationships with multiple global pharmaceutical collaborators,
including Genmab, Sanofi, Genentech, a member of the Roche Group,
Regeneron, Genevant, Fosun Pharma, and Pfizer. For more
information, please visit www.BioNTech.com.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “may,” “will,” “should,”
“likely,” “anticipates,” “expects,” “intends,” “plans,” “projects,”
“believes,” “estimates,” “outlook” and similar expressions are used
to identify these forward-looking statements. These forward-looking
statements include, but are not limited to, statements regarding
the Company’s intent to repurchase, from time to time, the
Company’s ADSs. Any forward-looking statements in this press
release are based on BioNTech’s current expectations and beliefs of
future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking. These risks and uncertainties include, but are not
limited to: changes in the market price of the Company’s ADSs,
general market conditions and applicable securities laws. For a
discussion of these and other as well as the risks, uncertainties
and other factors described in the Company’s filings with the
Securities and Exchange Commission. The “forward-looking
statements” included in this press release are made only as of the
date of this release. We do not have and do not undertake any
obligation to publicly update any “forward-looking statements” to
reflect subsequent events or circumstances, and we expressly
disclaim any such obligation, except as required by law or
regulation.
BioNTech Contacts
Investor RelationsMichael HorowiczTel: +1 (617) 955 7420 E-mail:
Investors@biontech.de
Media Relations Jasmina Alatovic Tel: +49 (0)6131 9084 1513
E-mail: Media@biontech.de
BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024